Pyxis Oncology Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 Commission File Number: 001-40881 Pyxis Oncology, Inc.(Exact Name of Registrant as Specified in its Charter) 83-1160910(I.R.S. EmployerIdentification No.) Registrant’s telephone number, including area code: (617) 453-3596 Securities registered pursuant to Section 12(b) of the Act: Title of each classTradingSymbol(s)Name of each exchange on which registeredCommon Stock, par value $0.001 per sharePYXSNasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☒ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 13, 2026, the registrant had 63,355,482 shares of common stock, $0.001 par value per share, outstanding. Table of Contents PageSummary Risk Factors1PART I.FINANCIAL INFORMATION3Item 1.Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20253Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months EndedMarch 31, 2026 and 20254Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2026and 20255Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20256Notes to Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations16Item 3.Quantitative and Qualitative Disclosures About Market Risk24Item 4.Controls and Procedures24PART II.OTHER INFORMATION26Item 1.Legal Proceedings26Item 1A.Risk Factors26Item 2.Unregistered Sales of Equity Securities and Use of Proceeds66Item 3.Defaults Upon Senior Securities66Item 4.Mine Safety Disclosures66Item 5.Other Information66Item 6.Exhibits67Signatures68 SUMMARY RISK FACTORS You should consider carefully the risks described under “Risk Factors” in Part II, Item 1A of this Quarterly Report onForm 10-Q. References to “Pyxis Oncology,” the “Company,” “we,” “us,” and “our” in this section titled “Summary Risk Factors”refer to Pyxis Oncology, Inc. and its wholly owned subsidiaries. A summary of the risks that could materially and adversely affectour business, financial condition, operating results and prospects include the following: •We are a clinical stage oncology company with a limited operating history and have incurred significant losses sinceour inception and anticipate that we will continue to incur losses over at least the next several years and may neverachieve or maintain profitability.•We have substantial doubt about our ability to continue as a going concern and we will require substantial additionalcapital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we maynot be able to continue as a going concern or we may be forced to delay, reduce or eliminate one or more of ourresearch and product development programs or future commercialization efforts.•We are heavily dependent on the success of our lead product candidate, micvotabart pelidotin (MICVO), formerlyknown as PYX-201, which is in the early stages of clinical development. If our lead product candidate is not successfulin clinical trials or does not receive regulatory approval or licensure or is not successfully commercialized, our businesswill be materially and adversely affected.•Our product candidate may fail in development or suffer delays that materially and adversely a